<DOC>
	<DOCNO>NCT01416987</DOCNO>
	<brief_summary>This prospective study collect safety information 600 patient treated Pergoveris® . During Post-Marketing Surveillance ( PMS ) period , data patient´s background , patient 's medical history , Pergoveris® indication , prior infertility medication , Pergoveris® treatment status , concomitant drug , adverse event ( regardless causal relationship Pergoveris® ) efficacy ( follicular growth clinical pregnancy ) collect study purpose . The post marketing surveillance base case treat Pergoveris® .</brief_summary>
	<brief_title>A Korean Post-Marketing Surveillance Study On Pergoveris® ( Follitropin Alfa + Lutropin Alfa )</brief_title>
	<detailed_description />
	<mesh_term>Infertility</mesh_term>
	<mesh_term>Follicle Stimulating Hormone</mesh_term>
	<criteria>Patients , eligible Pergoveris® treatment accord indication national label Pergoveris® . The national label approve Korea Food &amp; Drug Administration `` Pergoveris® association follicle stimulate hormone ( FSH ) preparation recommend stimulation follicular development woman severe Luteinizing Hormone ( LH ) FSH deficiency . In clinical trial patient define endogenous serum LH level &lt; 1.2 IU/L '' According national label</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>